Atrial Natriuretic Peptide (ANP): Physiology and Clinical Applications
ANP is a cardiac hormone primarily synthesized and stored in atrial granules that regulates blood pressure and fluid balance through natriuresis, diuresis, and vasodilation while antagonizing the renin-angiotensin-aldosterone system. 1
Physiological Mechanisms
ANP functions as part of the heart's endocrine system with multiple interconnected effects:
Cardiovascular and Renal Effects:
- Promotes natriuresis and diuresis by acting on channels in the renal nephron to inhibit sodium reabsorption 1, 2
- Induces vasodilation through vascular smooth muscle relaxation and pulmonary smooth muscle relaxation 1
- Lowers blood pressure through both direct vascular effects and volume reduction 3, 4
Neuroendocrine Antagonism:
- Inhibits the renin-angiotensin-aldosterone system and sympathetic nervous system activity 1
- Reduces secretion of arginine-vasopressin and corticotrophin in the central nervous system 1
- Decreases sympathetic tone and inhibits salt appetite and water drinking 1
Cardiac Structural Effects:
- Provides anti-hypertrophic function in the heart independent of blood pressure lowering 3
- Modulates myocardial and vascular structure through anti-proliferative and cytoprotective effects 1
Molecular Mechanism
ANP exerts its biological activities through binding to natriuretic peptide receptor-A (NPR-A), which is a guanylyl cyclase-coupled receptor 1, 4. This binding triggers production of cyclic GMP as a second messenger, which regulates ion channels, protein kinases, and phosphodiesterases 1.
Under normal conditions, ANP is primarily produced and stored in the atria in granules, making it readily available for immediate release in response to atrial stretch 1. This differs from BNP, which requires de novo synthesis.
Clinical Applications
Diagnostic Use in Heart Failure:
The most established clinical application of ANP and related natriuretic peptides (particularly BNP and NT-proBNP) is as biomarkers for diagnosis and prognosis of heart failure 5, 1. The 2017 American Heart Association scientific statement emphasizes that natriuretic peptides provide crucial information about disease severity and help with detection, diagnosis, prognosis, and management of HF 5.
Diagnostic thresholds for excluding heart failure in symptomatic patients:
- BNP levels < 35 pg/mL
- NT-proBNP levels < 125 pg/mL 6
Important caveats: ANP and natriuretic peptides are quantitative markers related to the extent of left ventricular wall tension 1. They increase non-specifically in all edematous disorders with salt and fluid overload, renal failure, and aging 1, 2. This means elevated levels do not automatically confirm cardiac dysfunction and must be interpreted in clinical context.
Therapeutic Applications:
- ANP infusion has demonstrated potential in management of acute or chronic heart failure 2, 7
- Recombinant proteins and small molecules that enhance the ANP pathway have been developed for HF treatment 3
- The increasing use of angiotensin receptor-neprilysin inhibitors (which prevent degradation of natriuretic peptides by neprilysin) has renewed clinical interest in ANP's therapeutic effects 4
Pathophysiological Significance:
In heart failure, there is a shift in ANP production from atria to ventricles in response to pressure or volume overload, as ventricular myocytes re-express fetal genes including ANP 1. However, HF is characterized by altered natriuretic peptide processing with secretion of less biologically active forms, explaining the "natriuretic peptide paradox" where administered BNP shows beneficial effects despite high endogenous immunoreactive natriuretic peptide levels 1.
Clinical associations with ANP variants include hypertension, stroke, coronary artery disease, heart failure, and obesity 3. ANP deficiency in mice causes salt-sensitive hypertension and cardiac hypertrophy 3.